Clinical Trials Logo

Phototoxicity clinical trials

View clinical trials related to Phototoxicity.

Filter by:
  • None
  • Page 1

NCT ID: NCT03892564 Completed - Phototoxicity Clinical Trials

Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream

Start date: February 27, 2019
Phase: Phase 1
Study type: Interventional

This trial is a 4-day, randomized study to determine the phototoxic potential of MC2-01 Cream when topical application to healthy skin is followed by light exposure.

NCT ID: NCT03108209 Completed - Phototoxicity Clinical Trials

Prevention of Phototoxicities in Patients Undergoing Vemurafenib Treatment

Start date: July 2016
Phase: N/A
Study type: Interventional

Vemurafenib is an anti-cancer treatment indicated as monotherapy in the treatment of adult patients with non-resectable or metastatic melanoma carrying a BRAF V600 mutation. Cobimetinib is indicated in combination with Vemurafenib in the treatment of adult patients with non-resectable or metastatic melanoma carrying a BRAF V600 mutation. These treatments are associated with a lot of adverse reactions, which may lead to dose reduction, temporary interruption or discontinuation of treatment, which often leads to treatment failure or a decrease in treatment compliance. The most commonly reported adverse reactions (> 30%) with Vemurafenib are arthralgia, rash, photosensitivity reaction, nausea, alopecia and pruritus. The most commonly reported adverse events (> 20%) associated with Cobimetinib / Vemurafenib are diarrhea, rash, nausea, pyrexia, photosensitivity reaction, increase of alanine aminotransferase, elevation of aspartate aminotransferase, blood creatine phosphokinase elevation and vomiting. The risk of presenting a phototoxicity adverse event with Vemurafenib in monotherapy or in combination with Cobimetinib is very common (≥ 1/10) according to MedDRA. The use of optimal photoprotection including the repeated daily use of external photoprotection products is currently recommended for all patients receiving treatment with vemurafenib or with the combination of vemurafenib and cobimetinib.